Dopavision Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $14.3M

  • Investors
  • 9

Dopavision General Information

Description

Developer of a digital therapeutic technology designed to slow down myopia progression in children and adolescents. The company's technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth, enabling health professionals to treat myopia with a clinically validated therapy.

Contact Information

Website
www.dopavision.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Pfuelstraße 5
  • Aufgang V
  • 10997 Berlin
  • Germany
+49 0821
Primary Industry
Therapeutic Devices
Other Industries
Application Software
Other Healthcare Technology Systems
Vertical(s)
LOHAS & Wellness, Digital Health, HealthTech, Life Sciences
Corporate Office
  • Pfuelstraße 5
  • Aufgang V
  • 10997 Berlin
  • Germany
+49 0821

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dopavision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 14-Jul-2021 $14.3M Completed Clinical Trials - General
3. Accelerator/Incubator 30-Jun-2020 Completed Clinical Trials - General
2. Seed Round 21-Jun-2019 $1.35M $1.35M Completed Clinical Trials - General
1. Grant $1.57M Completed Startup
To view Dopavision’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Dopavision Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a digital therapeutic technology designed to slow down myopia progression in children and adolescents. The
Therapeutic Devices
Berlin, Germany
9 As of 2026

Seoul, South Korea
 

Lod, Israel
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dopavision Competitors (3)

One of Dopavision’s 3 competitors is S-Alpha Therapeutics, a Venture Capital-Backed company based in Seoul, South Korea.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
S-Alpha Therapeutics Venture Capital-Backed Seoul, South Korea
NovaSight Venture Capital-Backed Lod, Israel
Tilak Venture Capital-Backed Paris, France
You’re viewing 3 of 3 competitors. Get the full list »

Dopavision Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Dopavision Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4271471-B1 Apparatus for selective application of stimulus light Active 08-Jun-2021
EP-4271471-C0 Apparatus for selective application of stimulus light Active 08-Jun-2021
CA-3221754-A1 Method and apparatus for selective application of stimulus light Pending 08-Jun-2021
EP-4271471-A1 Method and apparatus for selective application of stimulus light Active 08-Jun-2021
US-20240261590-A1 Method and apparatus for selective application of stimulus light Pending 08-Jun-2021 A61N5/0622
To view Dopavision’s complete patent history, request access »

Dopavision Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dopavision Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ababax Corporation Minority
dRx Capital Novartis Venture Capital Minority
Novartis Corporation Minority
Seventure Venture Capital Minority
German Accelerator Accelerator/Incubator
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Dopavision FAQs

  • When was Dopavision founded?

    Dopavision was founded in 2017.

  • Where is Dopavision headquartered?

    Dopavision is headquartered in Berlin, Germany.

  • What is the size of Dopavision?

    Dopavision has 9 total employees.

  • What industry is Dopavision in?

    Dopavision’s primary industry is Therapeutic Devices.

  • Is Dopavision a private or public company?

    Dopavision is a Private company.

  • What is the current valuation of Dopavision?

    The current valuation of Dopavision is .

  • What is Dopavision’s current revenue?

    The current revenue for Dopavision is .

  • How much funding has Dopavision raised over time?

    Dopavision has raised $15.6M.

  • Who are Dopavision’s investors?

    Ababax, dRx Capital Novartis, Novartis, Seventure, and German Accelerator are 5 of 9 investors who have invested in Dopavision.

  • Who are Dopavision’s competitors?

    S-Alpha Therapeutics, NovaSight, and Tilak are competitors of Dopavision.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process